In Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory Approaches

被引:47
作者
Forbes, Ben [1 ]
Backman, Per [2 ]
Christopher, David [3 ]
Dolovich, Myrna [4 ]
Li, Bing V. [5 ]
Morgan, Beth [6 ]
机构
[1] Kings Coll London, Inst Pharmaceut Sci, London SE1 9NH, England
[2] AstraZeneca R&D, Molndal, Sweden
[3] Merck Res Labs, West Point, PA USA
[4] McMaster Univ, Hamilton, ON, Canada
[5] US FDA, Silver Spring, MD USA
[6] GlaxoSmithKline, Zebulon, NC USA
关键词
aerosol; bioequivalence; deposition; dissolution; in vitro-in vivo correlation; inhaler; regulatory; statistics and data analysis; COMPUTATIONAL FLUID-DYNAMICS; REGIONAL LUNG DEPOSITION; PERFUSED RAT LUNG; COMPUTED-TOMOGRAPHY; AEROSOL DEPOSITION; PARTICLE AEROSOLS; EPITHELIAL-CELLS; DRUG DEPOSITION; INHALATION; ABSORPTION;
D O I
10.1208/s12248-015-9763-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This article is part of a series of reports from the "Orlando Inhalation Conference-Approaches in International Regulation" which was held in March 2014, and coorganized by the University of Florida and the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS). The goal of the conference was to foster the exchange of ideas and knowledge across the global scientific and regulatory community in order to identify and help move towards strategies for internationally harmonized, science-based regulatory approaches for the development and marketing approval of inhalation medicines, including innovator and second entry products. This article provides an integrated perspective of case studies and discussion related to in vitro testing of orally inhaled products, including in vitro-in vivo correlations and requirements for in vitro data and statistical analysis that support quality or bioequivalence for regulatory applications.
引用
收藏
页码:837 / 852
页数:16
相关论文
共 113 条
[31]  
[Anonymous], IPAC RS ORL INH C 18
[32]  
[Anonymous], FDA GUID IND PAT FRA
[33]  
[Anonymous], IPAC RS ORL INH C 18
[34]  
[Anonymous], P AAPS ANN M
[35]  
[Anonymous], IPAC RS ORL C 18 20
[36]   In Vitro Aqueous Fluid-Capacity-Limited Dissolution Testing of Respirable Aerosol Drug Particles Generated from Inhaler Products [J].
Arora, Deepika ;
Shah, Kumar A. ;
Halquist, Matthew S. ;
Sakagami, Masahiro .
PHARMACEUTICAL RESEARCH, 2010, 27 (05) :786-795
[37]   Advances in Inhaled Technologies: Understanding the Therapeutic Challenge, Predicting Clinical Performance, and Designing the Optimal Inhaled Product [J].
Backman, P. ;
Adelmann, H. ;
Petersson, G. ;
Jones, C. B. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (05) :509-520
[38]  
Batley DL, 2006, J AEROSOL MED, V19, P1
[39]   Development of a novel model for comparative evaluation of intranasal pharmacokinetics and effects of anti-allergic nasal sprays [J].
Baumann, Daniel ;
Bachert, Claus ;
Hoegger, Petra .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2012, 80 (01) :156-163
[40]   Regional distribution and kinetics of inhaled pharmaceuticals [J].
Berridge, MS ;
Lee, ZH ;
Heald, DL .
CURRENT PHARMACEUTICAL DESIGN, 2000, 6 (16) :1631-1651